The validation comes from the National Institute on Alcohol Abuse and Alcoholism, Revia maker DuPont Merck Pharmaceutical Company reported in a news release Dec. 22. This study proves Revia is clinically useful medication that can bridge the gap that exists between pharmacotherapy and psychosocial treatment modalities to increase the retention rate of alcoholic patients in treatment. A total of 865 patients were followed for the latest study. All patients were already participating in treatment programs for alcohol recovery, the press release said. During the holidays we see many relapses from stable, recovering alcoholics.
Naltrexone helps an alcohol-dependent person keep control by reducing craving for the first drink.
The results of the latest study have been published in the December issue of the Archives of General Psychiatry . .